(Q36830674)

English

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum

scientific article published on March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

10

object named as

Dennis S Chi

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Richard R Barakat

9

object named as

Richard R Barakat

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

7

object named as

Yukio Sonoda

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nadeem R. Abu-Rustum

8

object named as

Nadeem R Abu-Rustum

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Oliver Zivanovic

1

object named as

Oliver Zivanovic

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

object named as

Alexia Iasonos

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

William J. Hoskins

4

object named as

William J Hoskins

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

2

object named as

Camelia S Sima

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Pavani R Pingle

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Mario M M Leitao

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

1 March 2010

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

116

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

351-357

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Advanced cytoreductive surgery: American perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

29 September 2017

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

27 June 2018

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

27 June 2018

The impact of subspecialty training on the management of advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

27 June 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

5 September 2018

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

4 December 2018

Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843127

4 December 2018

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.022

7 January 2021

Primary cytoreductive surgery for epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20022092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2009.11.022

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36830674&oldid=1857412407"